Steven Valiquette
Stock Analyst at Mizuho
(3.36)
# 992
Out of 5,090 analysts
120
Total ratings
53.12%
Success rate
2.82%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LFMD LifeMD | Maintains: Neutral | $8 → $6 | $3.50 | +71.43% | 2 | Nov 19, 2025 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $5 → $4 | $2.71 | +47.60% | 1 | Nov 6, 2025 | |
| COR Cencora | Maintains: Outperform | $340 → $380 | $339.66 | +11.88% | 3 | Nov 6, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $170 → $210 | $198.83 | +5.62% | 7 | Nov 4, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $48 → $50 | $34.35 | +45.56% | 2 | Oct 30, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $210 → $170 | $157.21 | +8.14% | 12 | Oct 13, 2025 | |
| MCK McKesson | Maintains: Neutral | $750 → $770 | $808.62 | -4.78% | 4 | Sep 24, 2025 | |
| VEEV Veeva Systems | Maintains: Outperform | $295 → $325 | $242.00 | +34.30% | 4 | Aug 29, 2025 | |
| PHR Phreesia | Initiates: Outperform | $36 | $20.29 | +77.43% | 1 | Aug 27, 2025 | |
| NVST Envista Holdings | Maintains: Underperform | $15 → $18 | $20.23 | -11.02% | 2 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $7.59 | +31.75% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $60 | $45.93 | +30.63% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $18 | $11.25 | +60.00% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $82 | $85.43 | -4.01% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $94.51 | +33.32% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $75 | $73.62 | +1.87% | 5 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.08 | +62.34% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $14 | $2.59 | +440.54% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $231.08 | -38.55% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $80.61 | -31.77% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $204.31 | -54.97% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $330.91 | +70.74% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $75.63 | +32.22% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $5.48 | +155.47% | 1 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $151.86 | +163.40% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $38.34 | +179.08% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $37.70 | -54.91% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $10.78 | +11.32% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $112.50 | -14.67% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $182.51 | -34.25% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $486.70 | -73.91% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $257.85 | +38.84% | 3 | Dec 6, 2019 |
LifeMD
Nov 19, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $3.50
Upside: +71.43%
GoodRx Holdings
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $2.71
Upside: +47.60%
Cencora
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $339.66
Upside: +11.88%
Cardinal Health
Nov 4, 2025
Maintains: Outperform
Price Target: $170 → $210
Current: $198.83
Upside: +5.62%
Waystar Holding
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $34.35
Upside: +45.56%
Align Technology
Oct 13, 2025
Maintains: Outperform
Price Target: $210 → $170
Current: $157.21
Upside: +8.14%
McKesson
Sep 24, 2025
Maintains: Neutral
Price Target: $750 → $770
Current: $808.62
Upside: -4.78%
Veeva Systems
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $242.00
Upside: +34.30%
Phreesia
Aug 27, 2025
Initiates: Outperform
Price Target: $36
Current: $20.29
Upside: +77.43%
Envista Holdings
Aug 1, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $20.23
Upside: -11.02%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $7.59
Upside: +31.75%
May 16, 2025
Maintains: Neutral
Price Target: $65 → $60
Current: $45.93
Upside: +30.63%
Mar 13, 2025
Maintains: Neutral
Price Target: $21 → $18
Current: $11.25
Upside: +60.00%
Mar 3, 2025
Maintains: Neutral
Price Target: $70 → $82
Current: $85.43
Upside: -4.01%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $94.51
Upside: +33.32%
Dec 4, 2024
Initiates: Neutral
Price Target: $75
Current: $73.62
Upside: +1.87%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $3.08
Upside: +62.34%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $18 → $14
Current: $2.59
Upside: +440.54%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $231.08
Upside: -38.55%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $80.61
Upside: -31.77%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $204.31
Upside: -54.97%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $330.91
Upside: +70.74%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $75.63
Upside: +32.22%
Feb 27, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $5.48
Upside: +155.47%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $151.86
Upside: +163.40%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $38.34
Upside: +179.08%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $37.70
Upside: -54.91%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $10.78
Upside: +11.32%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $112.50
Upside: -14.67%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $182.51
Upside: -34.25%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $486.70
Upside: -73.91%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $257.85
Upside: +38.84%